Tagged with Policy

France In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France Regional Health Agency during the COVID-19 pandemic, is more than familiar with both the French healthcare system and dealing with…

Morocco Aligned with the country’s 2021 development plan and the national project to extend health insurance to all of its citizens, Morocco has embarked on a sweeping healthcare reform. After a draft framework for an overhaul of the Moroccan healthcare system was brought forward last year, the plan has been backed…

Europe The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of amendments to the proposed European Commission (EC) pharmaceutical legislation reform, which the organisation has warned will further accelerate the loss…

Europe As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by reducing regulatory exclusivity, speeding up review processes and reinforcing supply chains…

USA PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to…

USA With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new law while deciding how to move forward in response to it. At the recent BIO CEO and Investor Conference, stakeholders…

Germany In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the country’s health insurance system by distributing the financial burden amongst all healthcare stakeholders, yet biopharma companies stand to be hit…

USA David H. Crean, Managing Partner for Cardiff Advisory, discusses the economic impact of the signing and implementation of the Inflation Reduction Act (IRA) on the biopharmaceutical industry and innovation.   America’s biopharmaceutical research companies are researching and developing new medicines to meet unmet needs and continuing research and development even…

France An early bronchiolitis outbreak has put French paediatric hospital services under pressure and forced the government to react with the provision of EUR 150 million in emergency funds, but this crisis is by no means the first for French healthcare. France’s healthcare system, based on a statutory health insurance (SHI)…

Brazil Although Brazil is one of the world’s top pharma markets, with the highest market value in Latin America, and has made major strides towards universal healthcare, the country continues to recover from its worst recession ever and the fallout from its disastrous COVID-19 response. Brazilian voters are preparing for a…

United Kingdom After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack of consistency and coordination as well as cases of discrimination within the system. As a result of the report, the…

Europe Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) shares her views on the pharma industry’s response to COVID-19 and Europe’s preparedness for future health crises. She also discusses the reach and ambition of the Pharma Strategy and addresses the issues around equitable access.   …